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Abstract
Background: Altered thyroid function and increased rates of N-terminal pro-B-Type natriuretic peptide (NT-pro-BNP)
are highly prevalent in coronary artery disease (CAD) patients with heart failure, and are associated with unfavorable
prognosis. This study was undertaken to examine the relationship and prognostic impact of thyroid hormones,
inflammatory biomarkers, and NT-pro-BNP on long-term outcomes in patients after acute coronary syndrome (ACS).
Methods: The study comprised of 642 patients (age 58 ± 10 years, 77 % male) attending an in-patient cardiac
rehabilitation program after experiencing ACS. Patients were evaluated for demographic, clinical and CAD risk factors as
well as thyroid hormones (e.g., fT3, fT4 level, fT3/fT4 ratio), inflammatory biomarkers (hs-CRP, IL-6) and NT-pro-BNP
levels. Data on fT3/fT4 ratio and NT-pro-BNP levels were not normally distributed and were natural-log transformed (ln).
Both all-cause (cumulative) and cardiac-related mortality were considered the primary outcomes of interest.
Results: According to the Cox model, age, NYHA class, (ln)NT-pro-BNP levels (HR 1.53, 95 % CI 1.13–2.07), fT4 level
(HR 1.15, 95 % CI 1.04–1.27), and (ln)fT3/fT4 ratio (HR 0.08, 95 % CI 0.02–0.32) were the most important predictors of
all-cause mortality among CAD patients after ACS. Similarly, age, NYHA class, (ln)NT-pro-BNP levels (HR 1.62, 95 % CI
1.11–2.36), fT4 (HR 1.15, 95 % CI 1.02–1.29) and (ln)fT3/fT4 ratio (HR 0.10, 95 % CI 0.02–0.55) independently predicted
cardiac-related mortality. Kaplan-Meier analyses provided significant prognostic information with the highest risk for
all-cause mortality in the low cut off measures of fT3/fT4 ratio <0.206 and NT-pro-BNP ≥290.4 ng/L (HR 2.03, 95 % CI
1.39–2.96) and fT4 level >12.54 pg/ml (HR = 2.34, 95 % CI 1.05–5.18). There was no association between hs-CRP, IL-6
and mortality in CAD patients after ACS.
Conclusions: Thyroid hormones (i.e., fT4 level and fT3/fT4 ratio) together with NT-pro-BNP level may be valuable and
simple predictors of long-term outcomes of CAD patients after experiencing ACS.
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Background
Thyroid hormones play a key role in cardiovascular regu-
lation through various physiological and pathological
manifestations [1, 2]. In recent years, increased attention
has been focused on various circulating biologically active
substances, collectively known as plasma biomarkers, and
their utility in coronary artery disease (CAD) and heart
failure (HF) prognosis [1–4]. Neurohormonal activation of
N-terminal pro-B-type natriuretic peptides (NT-pro-BNP)
remains one of the established markers for the detection
and evaluation of HF severity and is considered a prognos-
tic determinant of disease progression in CAD patients
[5–7]. NT-pro-BNP is an important biomarker in patients
with acute coronary syndrome (ACS) as it is a marker of
myocardial cell necrosis and a strong predictor of morbid-
ity and mortality [7, 8]. Increased NT-pro-BNP levels
predict cardiac-related mortality in HF patients [9–11].
Altered thyroid function in the absence of primary
thyroid disease is characterized by low total triiodothyr-
onine (T3), free T3 (fT3) levels with normal total thyrox-
ine (T4) and thyroid-stimulating hormone (TSH). This
is due to reduced enzyme 5′ monodeiodinase activity,
responsible for converting T4 into T3 in the peripheral
tissues [12, 13]. It has been established that low circulat-
ing T3 levels are common in patients with HF [2, 13,
14], acute myocardial infarction (MI), [3, 15–17] and are
linked with poor prognosis [18, 19]. The literature in this
area indicates disparate perspectives on the association
of thyroid hormones and NT-pro-BNP serum levels;
some authors have demonstrated that higher thyroid
function is associated with the higher NT-pro-BNP levels.
In contrast others have suggested that hypothyroidism al-
ters NT-pro-BNP concentrations [20, 21].
In CAD, the rupturing of a patient’s coronary plaque
triggers an inflammatory cascade [22]. Studies have re-
ported that interleukin-6 (IL-6) can stimulate BNP
expression and that IL-6 has a significant positive associ-
ation with NT-pro-BNP [23–25]. It has recently been
hypothesized that IL-6, a pleiotropic proinflammatory
cytokine, may exert an inhibitory effect on thyroid func-
tion and suggests the development of euthyroid sick syn-
drome in patients with systemic diseases [26–28].
Inflammatory marker C-reactive protein (CRP) is mainly
produced in response to IL-6 and plays many patho-
physiological roles in the inflammatory process in HF. It
was shown that IL-6 and CRP are all inversely correlated
with fT3 levels in patients with stable HF [29, 30].
Moreover, it has been demonstrated that the relative risk
for CAD is higher in people with more inflammatory bio-
markers such as CRP and IL-6 and NT-pro-BNP. These
biomarkers also have the prognostic value of cardiovascu-
lar events in HF patients [22]. NT-pro-BNP, thyroid hor-
mone and inflammatory biomarkers concentrations have
also been found to change in patients treated with primary
percutaneous coronary intervention following ACS [8, 13,
22]. However, the relationship between NT-pro-BNP, thy-
roid hormone and inflammatory biomarkers in patients
undergoing a cardiac rehabilitation programme following
ACS is not well described.
From a clinical perspective, understanding whether
thyroid hormones and inflammatory biomarkers play a
role in the relationship between NT-pro-BNP and mor-
tality, would assist in greater accuracy with respect to
the risk-stratification of CAD patients admitted to re-
habilitation program and would also provide the oppor-
tunity for early interventions to address clinical risk
factors and improve patient prognosis.
The primary objective of this study was to measure
the associations between thyroid hormones, inflamma-
tory biomarkers and NT-pro-BNP. The second aim of
the study was to examine the potential impact of thyroid
hormones, inflammatory biomarkers and NT-pro-BNP
on long-term outcomes in patients enrolled in an in-
patient cardiac rehabilitation program after ACS.
Methods
Study population
During the period from January 2006 until January 2013 a
total of 826 CAD patients consecutively attending an in-
patient cardiac rehabilitation program, at the Cardiovascu-
lar Rehabilitation Clinic of the Behavioral Medicine
Institute of the Lithuanian University of Health Sciences in
Palanga, Lithuania, were invited to participate in the study.
All patients were admitted to the rehabilitation program
after two weeks of in-hospital stationary treatment for ACS.
Patients were excluded from the present study if they had
history of thyroid or adrenal disease (n = 74), were actively
taking thyroid medications or amiodarone (n = 34), had in-
creased TSH (>3.7 μg/mL) concentrations indicating
hypothyroidism (n = 14) or decreased TSH (<0.5 μg/mL)
concentrations indicating hyperthyroidism (n = 10), had
high concentrations of anti-thyroid peroxidase antibodies
(anti-TPO ≥60 U/mL) indicating autoimmune thyroid dis-
ease (n = 15) or who declined the opportunity to participate
in the study (n = 37). The final study population meeting in-
clusion/exclusion criteria was comprised of 642 CAD pa-
tients (77 % men; mean age, 58 ± 9 years) after ACS. All
study participants took part in the exercise-based cardiac
rehabilitation program and received standard treatment for
secondary prevention of CAD according to the existing
guidelines of secondary prevention through cardiac re-
habilitation [31–33].
Study design
This was a prospective study approved by The Regional
Biomedical Research Ethics Committee. More details of
study design, recruitment, and procedures have been pub-
lished elsewhere [34, 35]. In short, the baseline measure
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was chosen to be patients’ assessment within three days of
admission to the rehabilitation program, once they signed
written informed consent. Eligible participants were evalu-
ated for demographic factors (e.g., age and gender), clinical
characteristics (e.g., New York Heart Association [NYHA]
functional class, left ventricular ejection fraction [LVEF]),
CAD risk factors (e.g., diabetes mellitus, smoking, hyper-
tension, body mass index, and dyslipidemia) and current
medication use. Blood samples were drawn for each par-
ticipant to evaluate individual levels of thyroid hormones,
NT-pro-BNP, high-sensitivity CRP (hs-CRP) and IL-6.
Follow-up data on mortality (time and cause of death)
was used in the analysis as the primary outcome of inter-
est. The data was primarily obtained from death certifi-
cates, post-mortem reports, and medical records. When
data could not be obtained from these sources, the study
team attempted to conduct telephone interviews with par-
ticipant family members to obtain self-report mortality
data or to contact the Causes of Death Register at the
Institute of Hygiene of the Lithuanian Ministry of Health.
In some cases, this outcome data was unavailable.
It should be noted that to be classified as a cardiac-
related death, documentation of arrhythmias or cardiac
arrest, death due to progressive HF or MI in the absence
of a precipitating factor was required. Sudden unex-
pected death was classified as cardiac death when it oc-
curred outside the hospital and was not followed up by
autopsy. Death caused by accidents was excluded. Both
cardiac-related and all-cause mortality (cumulative –
death from any natural cause) were ascertained.
Evaluation thyroid axis hormones, NT-pro-BNP, hs-CRP
and IL-6 concentrations
All participants had a blood sample collection on second
day after admission to the rehabilitation clinic. Venous
blood samples were drawn after a minimum 12 h overnight
fast for the evaluation of thyroid axis hormones, NT-pro-
BNP, hs-CRP and IL-6 concentrations. Blood was centri-
fuged and serum was frozen at –40 °C. Serum concentra-
tions of T3, fT3, T4, free T4 (fT4), TSH were analysed
using automated enzyme immunoassay analyser AIA 600/
21/1800 (Tosoh corporation, US) and radioimmunoassay
kit RIA (R-EW-125, Belgium) for reverse T3 (rT3). Normal
range for T3, from 70 to 170 ng/dL; fT3, from 2.0 to
4.0 pg/mL; rT3, from 9 to 35 nd/dl; T4, from 4,5 to
12.0 μg/dL; fT4, from 7.0 to 17.0 pg/mL; TSH, from 0.25 to
4.5 μIU/mL. Serum concentration of NT-pro-BNP and
IL-6 were assessed using radio-immunoassay method
(Roche Cobas analyser, Roche Diagnostics, UK). Normal
serum concentration of NT-pro-BNP and IL-6 are
<157 ng/L and from 0 to 7 pg/mL, respectively. Serum hs-
CRP concentrations were assessed using the chemilumines-
cent immunoassay method (Beckman Coulter Unicel DXC
600) with normal values of ≤0.3 mg/dL.
Statistical analysis
Data is expressed as mean ± standard deviation (SD) for
variables with Gaussian distribution and as median (25th–
75th percentile) for variables with non-normal distribution.
Distribution of measurements was assessed using
Kolmogorov-Smirnov test. Group comparisons were made
using Student t test, Mann–Whitney U test, Fisher’s exact
test, or chi-square test, as appropriate. Associations be-
tween continuous variables were assessed by Pearson
product–moment analysis (Pearson r) or Spearman rank
correlation analysis (Spearman r), as appropriate. Multivari-
ate regression models were created for NT-pro-BNP, in-
flammatory biomarkers, and thyroid hormones adjusting
for gender, age and body mass index. A two-tailed P value
<0.05 was regarded as significant. All variables were exam-
ined for normal distribution and natural-log transformed
(ln) when necessary. Univariate and multivariate Cox re-
gression analyses were used to determine the relative risks
(hazard ratio [HR]) for all-cause and cardiac-related mortal-
ity associated with demographic and clinical risk factors,
such as age, gender, hypertension, NYHA class, and dia-
betes mellitus, as well as with NT-pro-BNP, thyroid hor-
mones, thyroid hormones ratios, hs-CRP and IL-6 levels.
We also generated receiver operating characteristic
(ROC) curves to assess cut-off values for demographic,
clinical, thyroid hormones, inflammatory biomarkers
and NT-pro-BNP characteristics that would prognostic-
ally discriminate between non-survivors (all-cause mor-
tality) and survivors. We used the approach by DeLong
et al. [36] to compare the areas under the ROC curves
(AUCs) of demographic and clinical models with AUCs
from biomarkers and additive models.
Then, based on the cut-off values patients outcomes
were assessed using Kaplan-Meier curves; a log-rank
(Mantel-Cox) test was used to compare survival curves
and estimate HR. All tests were performed using software
SPSS for Windows, version 17.0 (SPSS Inc., Chicago,
USA) and MedCalc for Windows, version 12.5 (MedCalc
Software, Ostend, Belgium).
Results
Baseline socio-demographic variables, clinical character-
istics, CAD risk factors and the mean concentrations of
thyroid hormones, NT-pro-BNP, IL-6, hs-CRP and
current treatment of 642 patients are shown in Table 1.
During the follow-up period (i.e., maximum of
118 months) there were 23 cardiac-related and 35 all-
cause deaths. Death most frequently occurred following
MI and the patients who died tended to be older, have a
higher NYHA functional class, lower LVEF, have more se-
vere hypertension, were more likely to have used nitrates
and to have higher concentrations of NT-pro-BNP, hs-
CRP, T4, fT4 and lower concentrations of fT3 during the
rehabilitation period at baseline assessment, as compared
to survivors (Table 1).
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Associations between thyroid hormones, hs-CRP, IL-6 and
NT-pro-BNP
There were significant correlations between (ln)fT3 and
fT4 levels (r = 0.179, p < 0.001), and (ln)fT4 and T3 (r =
0.112, p = 0.02). Significant correlations were also found
between (ln)rT3 and fT4 (r = 0.776, p < 0.001). There
were also strong correlation between (ln)hs-CRP and
(ln)IL-6 serum concentrations (r = 0.650, p < 0.001) and
Table 1 Patients characteristics





n = 642 n = 607 n = 35
Age (years), mean ± SD 57.6 ± 9.5 57.4 ± 9.4 62.3 ± 9.2 0.004
Gender, n (%) 0.382
Men 493 (76.8) 464 (76.4) 29 (82.9)
Women 149 (23.2) 143 (23.6) 6 (17.1)
Body mass index, mean ± SD 29.8 ± 4.7 29.9 ± 4.7 29.0 ± 5.2 0.355
Diagnosis, n (%) 0.010
Angina pectoris 159 (24.8) 149 (24.6) 10 (28.6)
Acute myocardial infarction 405 (63.1) 381 (62.8) 24 (68.6)
Previous myocardial infarction 78 (12.1) 77 (12.7) 1 (2.9)
Angina pectoris class, n (%) 0.063
I 143 (22.3) 138 (22.8) 5 (14.3)
II 214 (33.3) 196 (32.3) 18 (51.4)
III 18 (2.8) 16 (2.6) 2 (5.7)
NYHA, n (%) <0.001
I 52 (8.1) 52 (8.6) -
II 468 (72.9) 451 (74.2) 17 (48.6)
III 122 (19.0) 104 (17.2) 18 (51.4)
Hypertension, n (%) 0.001
Grade 1 (mild) 39 (6.1) 37 (6.1) 2 (5.7)
Grade 2 (moderate) 354 (55.2) 345 (56.8) 9 (25.7)
Grade 3 (severe) 109 (17.0) 96 (15.8) 13 (37.1)
Left ventricular ejection fraction %, mean ± SD 50.2 ± 9.0 50.5 ± 8.9 43.4 ± 8.2 0.001
Diabetes mellitus, n (%) 74 (11.5) 67 (11.1) 7 (20.0) 0.107
Nitrate, n (%) 255 (39.7) 233 (38.4) 22 (62.9) 0.004
Beta-blockers, n (%) 557 (86.8) 529 (87.3) 28 (80.0) 0.214
Angiotensin-converting enzyme inhibitors, n (%) 527 (82.1) 496 (81.8) 31 (88.6) 0.312
Diuretic, n (%) 101 (15.7) 92 (15.2) 9 (25.7) 0.096
N-terminal pro-B-Type natriuretic peptide (ng/L), median
(interquartile ranges)
328.3 (120.8–770.5) 303.7 (115.7–709.7) 570.0 (305.5–299.0) 0.001
hs-C-reactive protein (mg/dL), median (interquartile ranges) 0.26 (0.12–0.58) 0.26 (0.12–0.57) 0.47 (0.13–0.88) 0.077
Interleukin-6 (pg/ml), median (interquartile ranges) 3.1 (1.7–5.5) 3.1 (1.7–5.5) 3.7 (2.1–8.0) 0.209
Reverse Triiodothyronine (ng/ml), median (interquartile ranges) 0.27 (0.22–0.37) 0.27 (0.22–0.36) 0.30 (0.20–0.43) 0.375
Free Triiodothyronine (pg/ml), median (interquartile ranges) 2.80 (2.55–3.06) 2.80 (2.56–3.06) 2.72 (2.24–3.00) 0.036
Thyroid-stimulating hormone (μIU/ml), median (interquartile ranges) 1.8 (1.2–2.6) 1.8 (1.2–2.8) 1.7 (1.4–2.5) 0.875
Free Thyroxine (pg/ml), mean ± SD 13.0 ± 2.5 12.9 ± 2.4 14.6 ± 3.9 <0.001
Total Triiodothyronine (ng/dl), mean ± SD 106.7 ± 19.0 106.8 ± 19.0 104.3 ± 18.3 0.519
Total Thyroxine (μg/dl), mean ± SD 7.1 ± 1.5 7.8 ± 1.5 8.4 ± 1.4 0.042
Follow-up (months), mean ± SD 52.0 ± 29.2 52.5 ± 29.1 43.7 ± 30.6 0.029
NYHA New York Heart Association functional class
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between (ln)IL-6 and fT4 (r = 0.091, p = 0.03). The univari-
ate regression analysis indicated that higher (ln)NT-pro-
BNP levels were negatively correlated with concentrations
of (ln)fT3 (β = −0.112, p = 0.005), positively correlated with
concentrations of T4 (β = 0.126, p = 0.009), and (ln)TSH
(β = 0.097, p = 0.015). Biomarker (ln)NT-pro-BNP corre-
lated positively with fT4 (β = 0.100, p = 0.012). A lower
(ln)fT3/fT4 ratio was associated with higher (ln)NT-pro-
BNP (β = −0.112, p = 0.004). The positive association
between (ln)hs-CRP and (ln)NT-pro-BNP (β = 0.146,
p < 0.001), (ln)IL-6 (β = 0.228, p < 0.001, respectively)
was determined.
However, multivariate linear regression models, adjusted
for age, gender and body mass index, revealed that
(ln)NT-pro-BNP remain associated with hs-CRP (β = 0.59,
p < 0.001), (ln)IL6 (β = 0.254, p < 0.001), fT4 (β = 0.100,
p = 0.011), and T4 (β = 0.112, p = 0.019).
Prognostic impact of thyroid hormones and NT-pro-BNP
Univariate analysis of data showed that age, NYHA class,
(ln)NT-pro-BNP, (ln)rT3, fT4, (ln)fT3, and (ln)fT3/fT4
ratio were associated with all-cause mortality. Moreover
age, NYHA class, (ln)NT-pro-BNP, (ln)rT3, fT4, and
(ln)fT3/fT4 ratio were associated with cardiac-related
mortality (Table 2). A multivariate Cox regression model
showed that age (HR 1.06, 95 % CI 1.02–1.11, p = 0.003),
NYHA class (HR 3.01, 95 % CI 1.44–6.23, p = 0.003),
(ln)NT-pro-BNP levels (HR 1.53, 95 % CI 1.13–2.07, p =
0.006), fT4 level (HR 1.15, 95 % CI 1.04–1.27, p = 0.005),
and (ln)fT3/fT4 ratio (HR 0.08, 95 % CI 0.02–0.32, p <
0.001) were associated with all-cause mortality. However,
NYHA class (HR 3.58, 95 % CI 1.43–8.94, p = 0.006),
(ln)NT-pro-BNP levels (HR 1.62, 95 % CI 1.11–2.36, p =
0.013), fT4 level (HR 1.15, 95 % CI 1.02–1.29, p = 0.018)
and (ln)fT3/fT4 ratio (HR 0.10, 95 % CI 0.02–0.55, p =
Table 2 Cox regression analyses for factors associated with all-cause and cardiac-related mortality
Variable Univariate p-value Multivariatea p-value
HR (95 % CI) HR (95 % CI)
All-cause mortality
Age 1.07 (1.03–1.11) 0.001 1.06 (1.02–1.11) 0.003
Gender 0.67 (0.28–1.61) 0.368 0.52 (0.21–1.27) 0.150
Arterial Hypertension 0.98 (0.79–1.21) 0.821 0.97 (0.78–1.20) 0.785
Diabetes mellitus 2.26 (0.98–5.20) 0.055 2.00 (0.85–4.68) 0.111
NYHA class 4.32 (2.23–8.35 <0.001 3.01 (1.44–6.29) 0.003
(ln)NT-pro-BNP 1.56 (1.16–2.11) 0.004 1.53 (1.13–2.07) 0.006
(ln)hs-CRP 1.32 (0.99–1.76) 0.062 1.26 (0.93–1.71) 0.137
(ln)IL-6 1.39 (0.90–2.14) 0.138 1.21 (0.77–1.90) 0.398
fT4 1.17 (1.06–1.28) 0.002 1.15 (1.04–1.27) 0.005
(ln)fT3 0.12 (0.02–0.96) 0.045 0.14 (0.01–1.36) 0.089
(ln)fT3/fT4 0.09 (0.03–0.31) <0.001 0.08 (0.02–0.32) <0.001
(ln)rT3 2.29 (1.11–4.73) 0.025 2.15 (1.01–4.58) 0.049
Cardiac-related mortality
Age 1.06 (1.01–1.11) 0.023 1.05 (1.00–1.10) 0.062
Gender 1.12 (0.44–2.84) 0.815 0.79 (0.30–2.06) 0.623
Arterial Hypertension 1.02 (0.78–1.34) 0.871 1.06 (0.81–1.38) 0.688
Diabetes mellitus 1.35 (0.40–4.56) 0.627 1.08 (0.31–3.76) 0.899
NYHA class 6.01 (3.57–14.05) <0.001 3.58 (1.43–8.94) 0.006
(ln)NT-pro-BNP 1.65 (1.13–2.41) 0.009 1.62 (1.11–2.36) 0.013
(ln)hs-CRP 1.12 (0.78–1.60) 0.537 1.08 (0.75–1.56) 0.667
(ln)IL-6 1.41 (0.82–2.40) 0.213 1.35 (0.77–2.34) 0.293
fT4 1.17 (1.04–1.31) 0.007 1.15 (1.02–1.29) 0.018
(ln)fT3 0.13 (0.01–1.71) 0.122 0.23 (0.02–3.49) 0.287
(ln)fT3/fT4 0.09 (0.02–0.43) 0.002 0.10 (0.02–0.55) 0.008
(ln)rT3 2.46 (1.02–5.29) 0.045 2.05 (0.81–5.16) 0.128
HR hazard ratio, CI confidence interval, ln natural logarithm, hs-CRP high-sensitivity C-reactive protein, fT3 Free Triiodothyronine, fT4 Free Thyroxine, IL-6
Interleukin-6, NT-pro-BNP N-terminal pro-B-Type natriuretic peptide, rT3 Reverse triiodothyronine, NYHA New York Heart Association functional class
aFinal model: adjusted for age, arterial hypertension, diabetes mellitus, peripheral arterial disease
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0.008) remained independent predictors of cardiac-related
mortality. The hs-CRP and IL-6 levels were not found to
be associated with mortality (Table 2).
Figure 1 shows ROC curves for age and NYHA class.
Figures 2 and 3 show ROC curves and Kaplan-Meier
survival plots for biomarkers characteristics predicting
all-cause mortality. When participants were stratified
into high and low NT-pro-BNP level groups (cut-off
290.4 ng/L), the outcome (cumulative survival) for pa-
tients with high NT-pro-BNP levels was significantly
different in comparison to patients with low NT-pro-
BNP levels (HR 3.79, 95 % CI 1.57–9.15, p = 0.003)
(Fig. 2a). When patients were stratified into high and
low fT3/fT4 ratio groups (cut-off of <0.206), the outcome
for patients with lower fT3/fT4 ratio was significantly
worse than for patients with a higher fT3/fT4 ratio (HR
2.99, 95 % CI 1.43–6.26, p = 0.004) (Fig. 2b). ROC analysis
was used to assess the best cut-off values for fT4 levels
(cut-off 12.54 pg/ml) predicting all-cause mortality (AUC
0.63, 95 % CI 0.53–0.72, p = 0.013). When we stratified
participants into two groups according to cut-off
values, we found that higher fT4 levels were associ-
ated with worse outcomes (HR 2.34, 95 % CI 1.05–5.18,
p = 0.036) (Fig. 2c). When patients were subdivided
based on the cut-off values for fT3/fT4 ratio (of
<0.206) and NT-pro-BNP (≥290.4 ng/L) levels, the
outcomes for patients with a lower fT3/fT4 ratio and
higher NT-pro-BNP were worse, as compared with
the other groups (HR 2.03, 95 % CI 1.39–2.96, p <
0.001) (Fig. 3).
Data on how the AUCs from the demographic and
clinical predictors compares with the biomarkers alone
or combined models are presented in Table 3 and Fig. 4.
Overall, age and NYHA class showed good discrimin-
atory power for predicting all-cause mortality during fol-
low up. The NT-pro-BNP level and fT3/fT4 ratio model
had the best AUC of all isolated parameters. A combined
model comprising of age, NYHA class, NT-pro-BNP
level, and fT3/fT4 ratio showed the highest discrimin-
atory power among other predictors.
Evaluating all-cause mortality, the model comprised
of age, NYHA class, NT-pro-BNP level, and fT3/fT4
ratio was significantly better than age (difference be-
tween AUC: 0.150, 95 % CI 0.064–0.235, p < 0.001),
NYHA class (difference between AUC: 0.090, 95 % CI
0.030–0.150, p = 0.003), NT-pro-BNP level (difference
between AUC: 0.115, 95 % CI 0.023–0.207, p = 0.014), and
fT3/fT4 ratio (difference between AUC: 0.103, 95 % CI










Fig. 1 Receiver operating characteristic curves for age and NYHA class predicting all-cause mortality during follow up. NYHA – New York Heart
Association functional class. Area under the curve of age was 0.642 (95 % confidence interval [CI], 0.604–0.678; p = 0.003), of NYHA 0.690 (95 % CI,
0.653–0.725; p < 0.001)




















































































Fig. 2 (See legend on next page.)
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0.034–0.173, p = 0.218). However, it failed to perform sig-
nificantly better than NT-pro-BNP level and fT3/fT4 ratio
model.
Discussion
Our study demonstrated a significant relationship be-
tween the suppression of thyroid axis function, increased
inflammation markers and increased NT-pro-BNP levels
in CAD patients undergoing rehabilitation after ACS.
We have also demonstrated that measures of fT4 and
fT3/fT4 ratio together with NT-pro-BNP can be import-
ant prognostic markers of negative long-term outcomes
(i.e., mortality). We found no association between hs-
CRP and IL-6 and mortality among CAD patients.
A positive relationship between hs-CRP, IL-6 and NT-
pro-BNP was established in our study indicating that
thyroid function disturbances contribute to inflamma-
tory processes even during the rehabilitation period (i.e.,
after acute coronary events). Numerous studies have
confirmed fT3 and low-T3 syndrome as predictors of el-
evated NT-pro-BNP [7, 37]. The correlation of fT3 and
NT-pro-BNP was weaker in our study compared to Pfis-
ter et al. [37], which might be due to the dominant influ-
ence of cardiac abnormalities on NT-pro-BNP values in
our patients’ population. However, association of fT4
and NT-pro-BNP was evident in our study. Mayer et al.
[38] showed that even mild changes of fT4, still within
normal clinically accepted levels, may influence the bur-
den of HF as quantified by its biological surrogates (i.e.,
natriuretic peptides). Free thyroxine concentrations were
significantly positively associated with NT-pro-BNP and
BNP in a continuous manner. In this study association
was more evident at high-normal fT4 levels, than at
low-normal, where only the increase of a more sensitive
marker (NT-pro-BNP) was observed. Our findings add
to the developing understanding of the relationship be-
tween NT-pro-BNP, thyroid hormones and inflammatory
biomarkers in CAD patients during rehabilitation after
(See figure on previous page.)
Fig. 2 Receiver operating characteristics curves and Kaplan-Meier survival plots for a NT-pro-BNP, b fT3/fT4 ratio, and c fT4 values for predicting
all-cause mortality during follow-up. Results are the area under the curve (AUC) and associated 95 % confidence interval (CI). The best cut-off
values are labeled. A log-rank test was used to compare survival curves. NT-pro-BNP – N-terminal pro-B-Type natriuretic peptide, fT3/fT4 – Free
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Fig. 3 Kaplan-Meier survival plots for all-cause mortality for 642 CAD patients stratified into 4 groups based on cut-off values for NT-proBNP
(290.4 ng/L) and ratio fT3/fT4 (0.206) levels. fT3/fT4 – Free Triiodothyronine/Free Thyroxine ratio; NT-pro-BNP – N-terminal pro-B-Type natriuretic
peptide. The group with low fT3/fT4 ratio (<0.206) and high NT-proBNP (>290.4 ng/L) (bottom line) had a worse prognosis than others groups
(p < 0.001; by the log-rank test)
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ACS. Specifically, that NT-pro-BNP and thyroid hor-
mone level during rehabilitation could be an important
predictor of negative outcomes. Determining whether
these particular associations remain the same after re-
habilitation, and whether changes in these associations are
related to long term outcomes of CAD patients is beyond
the scope of this study but should be subject of further
investigation.
In the numerous prognostic studies, the altered thyroid
metabolism assessed by various parameters, indicated
Table 3 Receiver operating characteristic (ROC) curve evaluation for all-cause mortality prediction
Prediction of all-cause mortality: ROC analysis Area under the curve (AUC) 95 % CI p
Age 0.642 0.604–0.678 0.003
NYHA class 0.690 0.653–0.725 <0.001
NT-pro- BNP 0.675 0.638–0.711 <0.001
fT3/fT4 0.684 0.647–0.719 <0.001
NT-pro-BNP & fT3/fT4 model 0.732 0.693–0.766 <0.001
Combined model 0.800 0.753–0.817 <0.001
ROC curves comparison – Combined model vs: AUC (difference) 95 % CI p
Age 0.150 0.064–0.235 <0.001
NYHA class 0.090 0.030–0.150 0.003
NT-pro-BNP 0.115 0.023–0.207 0.014
fT3/fT4 0.103 0.034–0.173 0.004
NT-pro-BNP & fT3/fT4 model 0.055 −0.032–0.142 0.218
CI confidence interval, NT-pro-BNP N-terminal pro-B-Type natriuretic peptide, fT3/fT4 Free Triiodothyronine/Free Thyroxine ratio, fT4 Free Thyroxine, NYHA New York
Heart Association functional class; Combined model - composed by parameters of age, NYHA, NT-pro-BNP, and fT3/fT4












NT-pro-BNP &  fT3/fT4
Combined model
Fig. 4 Receiver operating characteristics curves of different parameters and models for predicting all-cause mortality during follow-up. NT-pro-
BNP – N-terminal pro-B-Type natriuretic peptide, fT3/fT4 – Free Triiodothyronine/Free Thyroxine ratio, NYHA – New York Heart Association
functional class. Combined model - composed by parameters of age, NYHA class, NT-pro-BNP, and fT3/fT4
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disturbed T4 peripheral conversion, such as a reduc-
tion in circulating levels of T3 [18, 39, 40], low T3
syndrome [19, 41–44], mild changes of fT4 [45], a
high rT3 level [46], a low fT3/rT3 ratio [46] and a
low fT3/fT4 ratio in serum [45].
Passino et al. [20] showed that monitoring the com-
bination of low fT3 and high BNP levels is a useful ap-
proach for determining long-term prognosis in patients
with advanced HF. Irrespective of the parameters used,
all these studies showed that altered peripheral thyroid
hormones pathways were associated with a high inci-
dence of fatal events (cumulative or cardiac-related
death). Low fT3 levels are the most common alternation
of thyroid hormones metabolism in patients with HF
and are related with the severity of HF. Presently, low
fT3 levels are found in approximately 20–30 % of pa-
tients with overt HF, 58 % of patients with advanced HF
and in less than 10 % of those with early HF [47]. Low
T3 reduction is more frequent in patients with NYHA
classes III-IV [12]. In the present study with CAD pa-
tients group (73 % with a NYHA II functional class,
63 % after acute MI) the fT3 levels have not exposed
prognostic impact to the long-term mortality. This
might be due to dominant influence of cardiac abnor-
malities on NT-pro-BNP values in our cohort or to
the recovered T3 level after ACS during the rehabili-
tation period [17]. Friberg et al. [17] showed that pa-
tients with poor heart function or who experienced a
more intense inflammatory reaction to acute MI,
showed more pronounced down-regulation of the thy-
roid hormones. The mean levels of the T3 declined
between the first 6 h and the 24–36 h period after
acute MI, although T3 levels were found to recover
within 12 weeks [17].
Our study also revealed that age, NYHA class, (ln)NT-
pro-BNP, fT4 and (ln)fT3/fT4 ratio were independent
predictors of all-cause mortality and that NYHA class,
(ln)NT-pro-BNP, fT4, (ln)fT3/fT4 ratio remained inde-
pendent predictors of cardiac-related mortality. Add-
itionally, it was demonstrated that higher levels of NT-
pro-BNP (≥290.4 ng/L) and a lower fT3/fT4 ratio
(<0.206) were independent predictors of cumulative
mortality. When patients were subdivided based on the
cut-off values for fT3/fT4 ratio and NT-pro-BNP levels,
the outcome for the patient group with the lower fT3/
fT4 ratio and higher NT-pro-BNP were found to be
worse, as compared with the other 3 groups.
However, there was no association between inflamma-
tory markers and mortality in our study. Conversely,
some authors have suggested that hs-CRP > 3.90 mg/L
and NT pro-BNP > 2247 pmol/L are associated with
all-cause mortality in dilated cardiomyopathy patients
[48, 49] and can be a potential predictors for all-
cause mortality [50].
Euthyroid sick syndrome is the most common type of
thyroid hormones abnormality where elevation of fT4
levels is frequently found. Friberg et al. [17, 40] showed
that rT3, the inactive metabolite of T3, is positively cor-
related with its precursor fT4, which suggests that fT4
levels can also be used instead of rT3. Higher levels of
rT3 and fT4 were associated with worse rates of survival,
that is, patients that died within the first week after
acute MI had a median free fT4 level of 16 pmol/L as
compared with 15 pmol/L in survivors. Similar differ-
ences were also seen after 1 month and 1 year. It was
also noted that in patients with a history of angina pec-
toris, the highest levels of fT4 were found in patients
classified with unstable angina pectoris. Jung et al. [51]
examined the association of thyroid function with CAD
in euthyroid angina pectoris patients and showed that
fT4 levels were associated with the presence and the se-
verity of CAD. Jung et al. [51] study also suggests that
elevated serum fT4 levels, even within normal range,
could be a risk factor for CAD. Our study extends the
data of Jung et al. [51] by showing that elevated fT4
levels during rehabilitation are related with long-term
mortality in CAD patients.
Kozdag et al. [45] studied a group of 111 patients with
ischemic and non-ischemic dilated cardiomyopathy and
advanced NYHA class (III-IV), and showed that patients
with lower fT3/fT4 ratio had a significantly less favor-
able outcome, as compared with those having higher
fT3/fT4 ratio during 12 months of follow-up. Studies
also find that NT-pro-BNP levels predict cardiac-related
mortality in HF patients and patients with congenital
heart disease [9–11, 52]. Recent review suggests that
NT-pro-BNP assessment alone could be a useful tool
predicting all-cause mortality in stable CAD patients
[53]. However, we found that not only higher levels of
NT-pro-BNP but also fT4 and lower fT3/fT4 ratio dur-
ing cardiac rehabilitation were associated with long-term
mortality in patients after ACS. Thus, in practical terms,
the determination of fT4 level and fT3/fT4 ratio to-
gether with NT-pro-BNP, are valuable and simple pre-
dictors for the identification of CAD patients that are
more likely to experience negative long-term outcomes
after cardiac rehabilitation.
However, despite this relationship, using fT4 levels as
a prognostic indicator in clinical settings will require
more research to establish its validity. For example, fu-
ture research could look at the influence of NT-pro-
BNP and inflammatory markers concentration changes
on fT4 levels in order to establish possible mediation/
moderation effects on mortality. In the present form our
findings may not be clinically relevant, but should be
used to create multifactorial risk for mortality models.
Despite our consistent results, there were some limita-
tions of the study that should be noted. Particularly, in
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terms of generalizability, as the majority of study partici-
pants had mild to moderate HF and all study patients
attended a single-center in-patient cardiac rehabilitation
program after being treated for ACS. Thus, the results
may not apply to patients with more advanced HF and
those who do not attend cardiac rehabilitation programs.
Another limitation of our study was that we did not
measure the fT3 level and other thyroid hormones in
acute stage of coronary syndromes and therefore did not
established variations of the fT3 before cardiac
rehabilitation.
Conclusions
This study demonstrated that thyroid hormones charac-
teristics such as fT4 level and fT3/fT4 ratio together
with NT-pro-BNP level may be valuable predictors of
long-term outcomes of CAD patients after experiencing
ACS. Additional research is needed to determine how
and when these prognostic indicators should be opera-
tionalized in a clinical setting and how treatment should
be prioritized in higher-risk cardiac rehabilitation
patients.
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